Esketamine Treatment: A New Dawn for Treatment-Resistant Depression
n the landscape of mental health treatment, the emergence of esketamine (SPRAVATO®) represents one of the most significant advances in decades for individuals battling treatment-resistant depression (TRD). For the estimated one-third of people with major depressive disorder (MDD) who find little relief from traditional oral antidepressants, this treatment offers a new, rapid-acting pathway to potential recovery. […]